• 18 November 2026
    • DOI:10.20944/preprints202611.1833.v1
Abstract
Background: Hymenoptera venom allergy is an important cause of anaphylaxis in children and adolescents, yet pediatric-specific data on sensitization patterns and their clinical relevance remain limited as are long-term data after venom immunotherapy (VIT). Objective: To characterize the clinical presentation, sensitization profile, and outcome of VIT in children and adolescents with Hymenoptera venom allergy. Methods: In this retrospective single-center study, 170 children and adolescents (0–18 years) who presented with a suspected sting-induced allergic reaction at a pediatric university hospital between 2013 and 2023 were identified. Seventy-three patients had confirmed venom allergy and initiated VIT; 44 returned a standardized follow-up questionnaire capturing symptoms at the index reaction, VIT tolerability, and outcome after field re-stings. Results: Yellow jacket and honeybee accounted for all confirmed cases. Cutaneous symptoms were the major findings at the index reaction (97.7%). Grade II reactions predominated (70.5%); grade IV reactions were absent. Baseline tryptase was within the normal range in the large majority of patients and showed no relationship with reaction severity. Component-resolved diagnostics confirmed Api m 1/Api m 10 and Ves v 1/Ves v 5 as the most frequently positive marker allergens, but sensitization patterns were not consistently associated with reaction severity. VIT was well tolerated, with a marked reduction in symptom frequency across all organ systems during therapy. Among 17 patients with a documented field re-sting, symptoms were substantially reduced compared with the index reaction but not eliminated. No severe reactions occurred after field stings. Adrenaline was used in only 15.9% of index reactions, and criteria for emergency kit discontinuation after VIT were applied inconsistently. Conclusions: Pediatric hymenoptera venom allergy is a distinct clinical entity in which classical adult risk factors and molecular sensitization profiles have limited prognostic value. VIT is safe and substantially reduces reactions risk after re-sting, supporting continued emergency preparedness and individualized, rather than time-based, emergency kit discontinuation.